Literature DB >> 17107992

ACE I/D but not AGT (-6)A/G polymorphism is a risk factor for mortality in ARDS.

M Adamzik1, U Frey, S Sixt, L Knemeyer, M Beiderlinden, J Peters, W Siffert.   

Abstract

The intrapulmonary renin-angiotensin system via tissue concentration of angiotensin II or bradykinin may have multiple effects on pulmonary pathophysiology. Therefore, it was investigated whether the presence of the D allele of the angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism or the A allele of angiotensinogen (AGT) promoter polymorphism (-6)A/G are independent risk factors for 30-day survival in acute respiratory distress syndrome (ARDS) patients. In a prospective study, adults (Germans of Caucasian ethnicity) with ARDS (n = 84) were recruited from the current authors' intensive care unit and genotyped for the ACE I/D and the AGT (-6)A/G polymorphisms, as were 200 healthy Caucasian controls. Mortality was increased in the ACE DD genotype compared with the I allele, and the ACE I/D polymorphism was an independent prognostic factor for 30-day survival. Patients with a homozygous DD genotype were at highest risk for death (hazard ratio 5.7; 95% confidence interval 1.7-19.2) compared with the II genotype. In contrast, the AGT (-6)A/G polymorphism was neither associated with an increased risk for development of ARDS nor with outcome. In patients with acute respiratory distress syndrome, the angiotensin-converting enzyme insertion/deletion polymorphism but not the angiotensinogen (-6)A/G promoter polymorphism is an independent risk factor with a pronounced effect on 30-day survival.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17107992     DOI: 10.1183/09031936.00046106

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  35 in total

Review 1.  Recent advances in genetic predisposition to clinical acute lung injury.

Authors:  Li Gao; Kathleen C Barnes
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-02-13       Impact factor: 5.464

Review 2.  Targeting tissue angiotensin-converting enzyme for imaging cardiopulmonary fibrosis.

Authors:  Omer Aras; Vasken Dilsizian
Journal:  Curr Cardiol Rep       Date:  2008-03       Impact factor: 2.931

Review 3.  Fifty Years of Research in ARDS. Genomic Contributions and Opportunities.

Authors:  John P Reilly; Jason D Christie; Nuala J Meyer
Journal:  Am J Respir Crit Care Med       Date:  2017-11-01       Impact factor: 21.405

Review 4.  Beyond single-nucleotide polymorphisms: genetics, genomics, and other 'omic approaches to acute respiratory distress syndrome.

Authors:  Nuala J Meyer
Journal:  Clin Chest Med       Date:  2014-09-23       Impact factor: 2.878

5.  Increased risk of pneumonia associated with angiotensin-converting enzyme (CD143) rs4340 polymorphism.

Authors:  Xiaofang Zhang; Fangzhu Liu
Journal:  Clin Exp Med       Date:  2015-05-16       Impact factor: 3.984

Review 6.  Diabetes, insulin, and development of acute lung injury.

Authors:  Shyoko Honiden; Michelle N Gong
Journal:  Crit Care Med       Date:  2009-08       Impact factor: 7.598

7.  Reciprocal congenic lines of mice capture the aliq1 effect on acute lung injury survival time.

Authors:  Daniel R Prows; Amanda P Hafertepen; Abby V Winterberg; William J Gibbons; Scott C Wesselkamper; Jonathan B Singer; Annie E Hill; Joseph H Nadeau; George D Leikauf
Journal:  Am J Respir Cell Mol Biol       Date:  2007-07-26       Impact factor: 6.914

Review 8.  A hypothesis for pathobiology and treatment of COVID-19: The centrality of ACE1/ACE2 imbalance.

Authors:  Krishna Sriram; Paul A Insel
Journal:  Br J Pharmacol       Date:  2020-05-22       Impact factor: 8.739

9.  Association between insertion/deletion polymorphism in angiotensin-converting enzyme gene and acute lung injury/acute respiratory distress syndrome: a meta-analysis.

Authors:  Akihisa Matsuda; Taro Kishi; Asha Jacob; Monowar Aziz; Ping Wang
Journal:  BMC Med Genet       Date:  2012-08-31       Impact factor: 2.103

Review 10.  Functional ACE2 deficiency leading to angiotensin imbalance in the pathophysiology of COVID-19.

Authors:  Joshua R Cook; John Ausiello
Journal:  Rev Endocr Metab Disord       Date:  2021-07-01       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.